Study guide

4.3 Collaborative Practice Agreements (CPAs) in Virginia

Virginia MPJE Pharmacy Jurisprudence Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Virginia Pharmacy Regulatory Framework & Licensure

1.1 Virginia Board of Pharmacy Structure, Authority & Inspections 1.2 Pharmacist Licensure, Examination & Reciprocity 1.3 License Maintenance, CE Requirements & Renewal

2 Chapter 2: Pharmacy Personnel, Roles & Disciplinary Oversight

2.1 Pharmacist-in-Charge (PIC) Responsibilities & Requirements 2.2 Pharmacy Technicians, Trainees & Interns 2.3 Supervision Ratios & Non-Pharmacist Task Boundaries 2.4 Disciplinary Grounds, Sanctions & Health Practitioners' Monitoring Program (HPMP)

3 Chapter 3: Prescriptive Authority & Prescription Requirements

3.1 Prescriber Scope of Authority in Virginia 3.2 Non-Controlled Prescriptions (Schedule VI) Validity & Refills 3.3 Controlled Substance Prescriptions (Schedules II-V) Requirements 3.4 Electronic Prescribing (EPCS) Mandates & Transmission Standards

4 Chapter 4: Clinical Pharmacy Practice, Counseling & Collaborative Care

4.1 Patient Counseling Standards & OBRA 90 Compliance 4.2 Pharmacist Immunization Authority & Administration Protocols 4.3 Collaborative Practice Agreements (CPAs) in Virginia 4.4 Statewide Protocols, Standing Orders & Naloxone Dispensing

5 Chapter 5: Controlled Substance Practice & Public Health Protections

5.1 Opioid Prescribing Limits, Acute Pain Rules & MME Thresholds 5.2 Drug Return, Repository Programs & Safe Disposal 5.3 Patient Confidentiality, HIPAA & Virginia Health Records Privacy

6 Chapter 6: Prescription Validation, PMP & Transfers

6.1 Corresponding Responsibility & Red Flag Evaluation 6.2 Virginia Prescription Monitoring Program (PMP) Mandates 6.3 Prescription Transfer Rules Between Pharmacies

7 Chapter 7: Dispensing Mechanics, Exceptions & Substitution

7.1 Prospective Drug Utilization Review (DUR) Standards 7.2 Emergency Refills & Schedule II Partial Fill Exceptions 7.3 Generic Substitution & Biosimilar Interchange in Virginia 7.4 Nonprescription Products, Methamphetamine Precursors & Schedule V Exempt Narcotics

8 Chapter 8: Labeling, Packaging & Product Integrity

8.1 Prescription Labeling Requirements & Expiration Dating 8.2 Poison Prevention Packaging Act (PPPA) & Child-Resistant Containers 8.3 Adulteration, Misbranding & FDA Drug Recall Classes

9 Chapter 9: Controlled Substance Ordering, DSCSA & Inventory

9.1 DEA Form 222, CSOS & Controlled Substance Ordering 9.2 Drug Supply Chain Security Act (DSCSA) Track-and-Trace 9.3 Pharmacy Security, Storage & Emergency Access Rules 9.4 Controlled Substance Inventories & Recordkeeping

10 Chapter 10: Theft Reporting, Compounding & Special Operations

10.1 Theft, Loss Reporting (DEA 106) & Disposal (DEA 41) 10.2 Non-Sterile and Sterile Compounding Standards (USP <795>, <797>) 10.3 Hazardous Drugs Handling (USP <800>) in Pharmacy Practice 10.4 Automated Dispensing Systems, Central Fill & Prescription Delivery

4.3 Collaborative Practice Agreements (CPAs) in Virginia

Key Takeaways Explain This Topic AI

Collaborative Practice Agreements are authorized by Va. Code 54.1-3300.1 and governed by 18VAC110-40 (Regulations Governing Collaborative Practice Agreements), jointly promulgated by the Boards of Pharmacy and Medicine.

CPAs authorize pharmacists to initiate, modify, continue, or discontinue drug therapy and order laboratory tests pursuant to a disease-specific written protocol approved by participating physicians.

A pharmacist may hold a CPA with a physician, osteopath, or podiatrist, with a physician's office, or directly with a licensed physician assistant or advanced practice registered nurse (Va. Code 54.1-3300.1 A).

Virginia fixes no annual re-execution deadline for a CPA; 18VAC110-40-40 requires only procedures for periodic review, and 18VAC110-40-60 lets either signatory or the patient terminate at any time.

Written informed consent must be obtained from each patient prior to enrolling them in collaborative drug therapy management, and the patient retains the statutory right to decline or withdraw consent at any time.

Last updated: September 2026

4.3 Collaborative Practice Agreements (CPAs) in Virginia

Collaborative drug therapy management represents a high level of clinical interprofessional practice in the Commonwealth of Virginia. Codified in the Code of Virginia at § 54.1-3300.1 and governed by joint regulations of the Board of Pharmacy and Board of Medicine at 18VAC110-40-10 et seq. , a Collaborative Practice Agreement (CPA) establishes a formal clinical partnership between pharmacists and medical practitioners.

Through a CPA, prescribers delegate specified patient management functions to pharmacists. Rather than contacting a physician for every minor dosage titration or routine refill authorization, the collaborative pharmacist exercises independent clinical judgment within the boundaries of a pre-approved, evidence-based treatment protocol.

Contracting Parties & Eligibility Requirements

Under Va. Code § 54.1-3300.1 , collaborative practice agreements may be established between one or more pharmacists and one or more physicians or healthcare practices:

1. Eligible Practitioners

Pharmacists: Must hold an active, unrestricted license to practice pharmacy issued by the Virginia Board of Pharmacy.

Physicians: Must hold an active, unrestricted license to practice medicine or osteopathy (MD or DO) issued by the Virginia Board of Medicine.

Nurse Practitioners (NPs) & Physician Assistants (PAs): An advanced practice registered nurse or physician assistant may participate in a CPA, provided that their underlying practice agreement with their collaborating physician authorizes such participation, or if the NP holds an autonomous practice license under Va. Code § 54.1-2957 .

2. Practice Settings

CPAs may be utilized across diverse healthcare delivery models in Virginia, including:

  • Inpatient health systems and academic medical centers;
  • Ambulatory care clinics and patient-centered medical homes (PCMH);
  • Independent primary care and specialty medical practices; and

Community pharmacies partnering with local physician groups for chronic disease management.

Scope of Clinical Management Authorized Under a CPA

Under Virginia law, collaborative drug therapy management is strictly disease-state and protocol-driven. Pharmacists are authorized to perform specific clinical interventions only to the extent explicitly delineated in the written agreement. Permissible Clinical Scope Under Virginia CPA (Va. Code § 54.1-3300.1):

  • ├── 1. Drug Regimen Management
  • │ ├── Initiating new drug therapy (within protocol parameters)
  • │ ├── Modifying dosages, dosage forms, and administration schedules
  • │ ├── Continuing maintenance therapy
  • │ └── Discontinuing therapy due to toxicity, lack of efficacy, or goal attainment
  • │
  • ├── 2. Laboratory & Diagnostic Testing
  • │ ├── Ordering laboratory tests (e.g., HbA1c, lipid panel, serum creatinine, INR)
  • │ ├── Performing point-of-care CLIA-waived diagnostic testing
  • │ └── Evaluating and interpreting laboratory test results
  • │
  • └── 3. Patient Physical Assessment & Monitoring
  • ├── Measuring vital signs (blood pressure, pulse, weight, BMI)
  • ├── Conducting disease-specific physical assessments
  • └── Evaluating adherence, side effects, and therapeutic response
  • Clinical Scope Boundaries & Prohibitions

No Independent Primary Diagnosis: A CPA does not authorize a pharmacist to diagnose medical conditions. The treating physician must establish the primary medical diagnosis (e.g., diagnosing Type 2 Diabetes or Hypertension) before the patient is referred into collaborative management.

Controlled Substance Limitations: A collaborative agreement cannot authorize a pharmacist to prescribe Schedule II controlled substances. Delegation of Schedules III through VI controlled substances must strictly adhere to the prescriber's statutory scope and the explicit terms of the protocol.

Scope Alignment: A physician may only delegate management of conditions that fall within the physician's normal scope of medical practice (e.g., an orthopedic surgeon cannot enter into a CPA to manage complex psychiatric disorders).

Mandatory Protocol and Agreement Components (18VAC110-40-40)

To be legally valid under Virginia Board regulations, every collaborative practice agreement must be in writing and contain the following mandatory statutory elements:

Mandatory Element Regulatory Specification (18VAC110-40-40)

Participating Practitioners Legal names, practice addresses, telephone numbers, and professional license numbers of all participating physicians and pharmacists.

Disease States & Indications Explicit list of the specific disease states, conditions, or drug therapies governed by the agreement (e.g., Anticoagulation, Diabetes Mellitus, Hypertension, Dyslipidemia, Asthma).

Clinical Decision Algorithms Detailed written protocols detailing baseline criteria, drug selection algorithms, dosing titration schedules, contraindications, and targeted therapeutic endpoints.

Authorized Laboratory Tests Complete list of laboratory and diagnostic tests the pharmacist is authorized to order, monitor, and interpret.

Emergency & Escalation Protocols Written procedures for managing acute adverse reactions, severe laboratory abnormalities, emergency clinical decompensation, and rapid physician referral.

Documentation & Notification Specific mechanisms and timeframes for documenting interventions and notifying the collaborating physician.

Signatures & Dates Manual or secure digital signatures of all participating practitioners with the date of execution.

Periodic Review and Rescindment (18VAC110-40-40, 18VAC110-40-60)

A frequently mis-taught point: Virginia does not fix a numeric re-execution interval for collaborative practice agreements. There is no regulation requiring annual renewal every 12 months. What 18VAC110-40-40 requires is that the signatories implement procedures for periodically reviewing the agreement and its protocol — the cadence is set by the parties in the agreement itself, not by the Board.

Two related obligations are fixed:

Notification on change: the signatories must notify the other party when the practice location or ownership changes (18VAC110-40-40).

Termination at will: under 18VAC110-40-60 , either signatory or the patient may terminate the agreement at any time, and the practitioner may override the agreement for a specific patient at any time.

Exam trap: If an option asserts that a Virginia CPA "expires" or "must be re-executed" after a set period such as 12 or 24 months, it is describing another state's rule. Virginia's requirement is periodic review on the parties' own schedule, plus termination at will.

Patient Informed Consent & Patient Rights (§ 54.1-3300.1)

Patient autonomy and informed consent are foundational safeguards under Virginia collaborative practice law:

Mandatory Written Informed Consent: Prior to initiating collaborative drug therapy management, the patient (or the patient's legal guardian) must provide written informed consent .

Required Disclosures: The consent document must clearly inform the patient that:

The pharmacist will be managing their drug therapy pursuant to an agreement with their physician;

The specific scope of services the pharmacist will provide (including adjusting medications and ordering tests); and

The patient has the absolute statutory right to decline participation or withdraw consent at any time without compromising their relationship with their physician or their regular medical care.

Consent Retention: A copy of the signed informed consent must be maintained in both the pharmacist's clinical record and the physician's medical chart.

Documentation and Reporting Back to the Practitioner (18VAC110-40-40)

Virginia does not publish a fixed clock — no 24-hour, 48-hour, or 7-day deadline — for a collaborative pharmacist to notify the practitioner of a therapy change. Instead, 18VAC110-40-40 requires the agreement itself to specify the pharmacist's authorized activities including procedures for documentation and for reporting activities and results to the practitioner . The controlling timeframe is therefore whatever the executed protocol states.

Where the regulation is prescriptive is record retention under 18VAC110-40-50 :

  • Record Who retains it Requirement
  • Copy of the collaborative agreement Both signatories Retained at their primary places of practice
  • The practitioner's order enrolling the patient Practitioner Noted in the patient's medical record
  • Patient's documented informed consent Practitioner Retained by the practitioner

Deviating from the terms of the agreement is not a paperwork problem: under Va. Code § 54.1-3300.1 C , a pharmacist who practices inconsistently with the agreement violates § 54.1-2902 (unlawful practice of medicine), which is grounds for discipline under §§ 54.1-2400 and 54.1-3316.

Loading diagram... Virginia Collaborative Practice Agreement (CPA) Lifecycle